TREATMENT OF CANCER WITH HEAVY CHARGED PARTICLES

为了测试改进剂量分布（氦）的潜在优势， 并且既改善了剂量分布又增加了生物效应（氖， 硅，氩），正在进行临床试验，以研究治疗 这些重带电粒子在治疗人类癌症中的应用。 分次、大野、展开布拉格峰带电粒子放射治疗 处理技术正在不断完善， 用于评估和补偿同质组织的技术 CT扫描仪以获得粒子束路径中的组织密度。 几个试点协议与氦已制定，导致迄今为止， 随机试验：氦离子治疗加5-FU与常规放疗 治疗加5-FU。 我们亦已展开第一至第二阶段的试验研究， 较重的离子，如碳、氖和氩。 我们的最终目标是测试 在一项随机试验中，重带电粒子与现有最佳治疗的对比 选择肿瘤。 现有的合作研究小组，如辐射 肿瘤治疗组和北方加州肿瘤组正在 用于促进这些试验，连同湾区重离子 协会

In order to test the potential advantages of improved dose distribution (helium) and both improved dose distribution and increased biological effect (neon, silicon, argon), a clinical trial is being conducted to study the therapeutic application of these heavy charged particles in the treatment of human cancers. Fractionated, large field, spread out Bragg peak charged particle radiotherapy treatment techniques are being continually refined together with improved techniques for assessment and compensation of tissue in homogeneities utilizing CT scanners to obtain tissue densities in the particle beam paths. Several pilot protocols with helium have been instituted, leading so far to one randomized trial: helium ion treatment plus 5-FU versus conventional radiation therapy plus 5-FU. We have also instituted Phase I-II pilot studies with heavier ions such as carbon, neon, and argon. Our ultimate goal is to test heavy charged particles against the best available therapy in a randomized trial of selected tumors. Existing cooperative study groups such as the Radiation Therapy Oncology Group and the Northern California Oncology Group are being utilized to facilitate these trials, together with the Bay Area Heavy Ion Association.